Hepadnaviruses (hepatitis B viruses) cause transient and chronic infections of the liver.
Transient infections run a course of several months, and chronic infections are often lifelong …

Cytokines are soluble proteins that allow for communication between cells and the external
environment. Interferon (IFN) alpha, the first cytokine to be produced by recombinant DNA …

Structural mutations in the p53 gene are seen in virtually every form of human cancer. To
determine whether such mutations are important for initiating tumorigenesis, we have been …

Hepatitis B virus (HBV) chronically infects 350–400 million people worldwide and causes> 1
million deaths yearly. Current therapies prevent new viral genome formation, but do not …

Objective: To investigate the clinical efficacy of adjuvant interferon alfa-2b (IFNα-2b) therapy
on recurrence-free survival (RFS) of patients with postoperative viral hepatitis-related …

Background/Aims: Lamivudine is highly effective in suppressing hepatitis B viral replication
and hepatic necroinflammatory activity. The potential for recovery of hepatic …

Hepatitis B after liver transplantation is often fatal, and no proven medical therapy exists for
this condition. We chose to study the potential efficacy of lamivudine therapy for patients with …

Objective: To estimate the cost-effectiveness of interferon-α2B for the treatment of patients
with chronic hepatitis B infection who are positive for hepatitis B e antigen (HBeAg). Design …

Thymosin α1 (Tα) is an immune modifier that has been shown in a pilot study to be effective
for chronic hepatitis B; this requires confirmation. Ninety‐eight patients with …

Background/Aims: Lamivudine is effective in treatment-naive patients with chronic hepatitis
B, but its role in interferon nonresponders has not been described. We assessed lamivudine …